Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, April 02, 2025. Let’s ...

Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce that the Corporation has ...

Equities researchers at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for shares of HLS Therapeutics ...

Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

Cintas Corporation CTAS shares jumped over 8% on Wednesday after the company posted better-than-expected third-quarter ...

Maravai LifeSciences Holdings Inc (MRVI) is expected to report $-0.07 for 4Q. McCormick & Co Inc (MKC) is expected to report $0.64 for 1Q. Movado Group Inc (MOV) is expected to report $0.39 for 4Q.

BioXcel Therapeutics, Inc., a pharmaceutical company with a market ... The initial warning was issued on September 20, 2024, after which BioXcel was given 180 days, until March 19, 2025, to meet the ...

MIAMI - Summit Therapeutics Inc. (NASDAQ ... The stock currently trades at $19.72, with InvestingPro analysis indicating the company maintains strong liquidity with a current ratio of 10.15. Vesting ...

On Friday, Canaccord Genuity revised its stance on Knight Therapeutics Inc. (GUD:CN) (OTC: KHTRF), downgrading the stock from a Buy to a Hold rating and adjusting the price target to C$6.50 from the ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...

John Fetterman and his wife, Gisele, in Jerusalem Wednesday where he gifted the Pennsylvania Democrat a silver pager inspired by last year’s attack against Hezbollah terrorists. “What can I ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the ...